{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T14:58:33Z","timestamp":1776610713710,"version":"3.51.2"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,4,5]]},"DOI":"10.18632\/oncotarget.7569","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T23:11:17Z","timestamp":1456182677000},"page":"18204-18218","source":"Crossref","is-referenced-by-count":19,"title":["Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies"],"prefix":"10.18632","volume":"7","author":[{"given":"Valentina","family":"Salizzato","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences and CNR Institute of NeuroSciences, University of Padova, 35131 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Borgo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and CNR Institute of NeuroSciences, University of Padova, 35131 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cesaro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and CNR Institute of NeuroSciences, University of Padova, 35131 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo A.","family":"Pinna","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and CNR Institute of NeuroSciences, University of Padova, 35131 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Donella-Deana","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and CNR Institute of NeuroSciences, University of Padova, 35131 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,2,22]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Stone","year":"1983","journal-title":"Nature"},{"key":"2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Saglio","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res"},{"key":"3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-012-0150-1","article-title":"Signal transduction in the chronic leukemias: implications for targeted therapies","volume":"8","author":"Van Etten","year":"2013","journal-title":"Curr. Hematol. Malig. Rep"},{"key":"4","first-page":"461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Talpaz","year":"2009","journal-title":"Hematol. Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Talpaz","year":"2011","journal-title":"Blood Rev"},{"key":"6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Schleyer","year":"2004","journal-title":"Leukemia"},{"key":"7","first-page":"122","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Cortes","year":"2009","journal-title":"Cancer Control J. Moffitt Cancer Cent"},{"key":"8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.molonc.2013.08.006","article-title":"Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives","volume":"7","author":"Donella-Deana","year":"2013","journal-title":"Mol. Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.bbapap.2012.12.009","article-title":"Mechanisms of resistance to BCR-ABL and other kinase inhibitors","volume":"1834","author":"Hantschel","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bbamcr.2009.01.013","article-title":"Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis","volume":"1793","author":"Pinna","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bbapap.2009.07.018","article-title":"Addiction to protein kinase CK2: a common denominator of diverse cancer cells?","volume":"1804","author":"Pinna","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"12","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.1021\/bi2008382","article-title":"Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer","volume":"50","author":"Pinna","year":"2011","journal-title":"Biochemistry (Mosc)"},{"key":"13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.advenzreg.2008.04.002","article-title":"Protein kinase CK2--a key suppressor of apoptosis","volume":"48","author":"Ahmed","year":"2008","journal-title":"Adv. Enzyme Regul"},{"key":"14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00018-009-9150-2","article-title":"Protein kinase CK2 in health and disease: From birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival","volume":"66","author":"Litchfield","year":"2009","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"15","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2011.385","article-title":"Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways","volume":"26","author":"Semenzato","year":"2012","journal-title":"Leukemia"},{"key":"16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1349-7006.2001.tb01161.x","article-title":"Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells","volume":"92","author":"Fojo","year":"2001","journal-title":"Jpn. J. Cancer Res. Gann"},{"key":"17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11010-008-9813-6","article-title":"Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis","volume":"316","author":"Ruzzene","year":"2008","journal-title":"Mol. Cell. Biochem"},{"key":"18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2010.79","article-title":"Synergistic activity of the Src\/Abl inhibitor bosutinib in combination with imatinib","volume":"24","author":"Gambacorti-Passerini","year":"2010","journal-title":"Leukemia"},{"key":"19","doi-asserted-by":"crossref","first-page":"e49193","DOI":"10.1371\/journal.pone.0049193","article-title":"Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells","volume":"7","author":"Ruzzene","year":"2012","journal-title":"PloS One"},{"key":"20","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1074\/jbc.M009134200","article-title":"The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation","volume":"276","author":"Pulido","year":"2001","journal-title":"J. Biol. Chem"},{"key":"21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.cdd.4401604","article-title":"Protein kinase CK2 phosphorylates and upregulates Akt\/PKB","volume":"12","author":"Ruzzene","year":"2005","journal-title":"Cell Death Differ"},{"key":"22","doi-asserted-by":"crossref","first-page":"31188","DOI":"10.1074\/jbc.M602618200","article-title":"Nuclear export of S6K1 II is regulated by protein kinase CK2 phosphorylation at Ser-17","volume":"281","author":"Gout","year":"2006","journal-title":"J. Biol. Chem"},{"key":"23","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1128\/MCB.05424-11","article-title":"Nuclear extracellular signal-regulated kinase 1 and 2 translocation is mediated by casein kinase 2 and accelerated by autophosphorylation","volume":"31","author":"Seger","year":"2011","journal-title":"Mol. Cell. Biol"},{"key":"24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/j.1460-2075.1991.tb08021.x","article-title":"Identification of the regulatory phosphorylation sites in pp42\/mitogen-activated protein kinase (MAP kinase)","volume":"10","author":"Sturgill","year":"1991","journal-title":"EMBO J"},{"key":"25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1042\/BJ20110289","article-title":"Regulation and function of the RSK family of protein kinases","volume":"441","author":"Roux","year":"2012","journal-title":"Biochem. J"},{"key":"26","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1242\/jcs.114.16.2903","article-title":"PKB\/Akt: a key mediator of cell proliferation, survival and insulin responses?","volume":"114","author":"Alessi","year":"2001","journal-title":"J. Cell Sci"},{"key":"27","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1007\/s00018-009-0108-1","article-title":"Dephosphorylation and inactivation of Akt\/PKB is counteracted by protein kinase CK2 in HEK 293T cells","volume":"66","author":"Ruzzene","year":"2009","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00726-010-0684-2","article-title":"Different cytoplasmic\/nuclear distribution of S6 protein phosphorylated at S240\/244 and S235\/236","volume":"40","author":"Hengstschl\u00e4ger","year":"2011","journal-title":"Amino Acids"},{"key":"29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20110892","article-title":"Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks","volume":"441","author":"Fingar","year":"2012","journal-title":"Biochem. J"},{"key":"30","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","article-title":"CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy","volume":"70","author":"Ryckman","year":"2010","journal-title":"Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"18623","DOI":"10.1074\/jbc.273.29.18623","article-title":"Identification of a novel inhibitor of mitogen-activated protein kinase kinase","volume":"273","author":"Scherle","year":"1998","journal-title":"J. Biol. Chem"},{"key":"32","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1074\/jbc.R109.094003","article-title":"Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony","volume":"285","author":"Fingar","year":"2010","journal-title":"J. Biol. Chem"},{"key":"33","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1038\/onc.2011.165","article-title":"Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2\/mTOR","volume":"30","author":"Hengstschl\u00e4ger","year":"2011","journal-title":"Oncogene"},{"key":"34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BJ20101024","article-title":"Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)","volume":"431","author":"Alessi","year":"2010","journal-title":"Biochem. J"},{"key":"35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Hall","year":"2006","journal-title":"Cell"},{"key":"36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/07853890600551037","article-title":"Targeting the ERK signaling pathway in cancer therapy","volume":"38","author":"Pouyssegur","year":"2006","journal-title":"Ann. Med"},{"key":"37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance","volume":"4","author":"Drexler","year":"2011","journal-title":"J. Hematol. Oncol.J Hematol Oncol"},{"key":"38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1349-7006.2009.01365.x","article-title":"Contribution of BCR-ABL-independent activation of ERK1\/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells","volume":"101","author":"Saito","year":"2010","journal-title":"Cancer Sci"},{"key":"39","first-page":"585","article-title":"BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML","volume":"39","author":"von Eggeling","year":"2011","journal-title":"Int. J. Oncol"},{"key":"40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev"},{"key":"41","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.bbapap.2010.04.009","article-title":"Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach","volume":"1804","author":"Salvatore","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.devcel.2007.03.020","article-title":"The Two TORCs and Akt","volume":"12","author":"Hay","year":"2007","journal-title":"Dev. Cell"},{"key":"43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.18632\/oncotarget.293","article-title":"Phosphorylation of AKT: a mutational analysis","volume":"2","author":"Vogt","year":"2011","journal-title":"Oncotarget"},{"key":"44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2012.02.032","article-title":"Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells","volume":"322","author":"Rice","year":"2012","journal-title":"Cancer Lett"},{"key":"45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/leu.2013.349","article-title":"Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling","volume":"28","author":"Locatelli","year":"2014","journal-title":"Leukemia"},{"key":"46","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2005.10.024","article-title":"mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events","volume":"123","author":"Blenis","year":"2005","journal-title":"Cell"},{"key":"47","first-page":"349","article-title":"One-thousand-and-one substrates of protein kinase CK2?","volume":"17","author":"Pinna","year":"2003","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol"},{"key":"48","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/15384101.2015.1006970","article-title":"BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation","volume":"14","author":"Saglio","year":"2015","journal-title":"Cell Cycle Georget. Tex"},{"key":"49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/B978-0-12-381298-8.00024-1","article-title":"Assessment of CK2 constitutive activity in cancer cells","volume":"484","author":"Pinna","year":"2010","journal-title":"Methods Enzymol"},{"key":"50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.abb.2014.01.006","article-title":"CK2 involvement in ESCRT-III complex phosphorylation","volume":"545","author":"Pinna","year":"2014","journal-title":"Arch. Biochem. Biophys"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T21:57:46Z","timestamp":1654379866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,22]]},"references-count":50,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2016,4,5]]}},"alternative-id":["7569","26919095"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.7569","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,22]]}}}